Brian Buntz

3 weeks ago | pharmaceuticalprocessingworld.com | Brian Buntz

The pharmaceutical supply chain ensures medications reach patients safely and on time. About 75% of pharma executives say supply chain disruptions threaten patient health. The industry faces particular concern now: according to the Global Supply Chain Pressure Index (GSCPI), global supply chains witnessed major issues during the COVID-19 pandemic and ongoing geopolitical tensions. Here are steps pharma companies are taking to keep medicines moving.

3 weeks ago | rdworldonline.com | Brian Buntz

Tokyo-based startup ispace has lost contact with its Resilience lander during a landing attempt at the Moon’s Mare Frigoris, a long lunar sea also dubbed the “Sea of Cold.” The mission’s likely failure marks a significant setback in the company’s second bid to achieve a commercial lunar touchdown. The first Hakuto-R mission (M1) in April 2023 after its software misjudged the lander’s altitude over a steep crater rim, causing it to run out of fuel while still about 5 km above the surface.

3 weeks ago | rdworldonline.com | Brian Buntz

Just over two months after R&D World covered the debut of Google’s experimental Gemini 2.5 Pro, the company has announced a significant upgrade following a prior May update to the model that drew mixed reactions from developers. Google’s latest Gemini 2.5 Pro has jumped to the top of AI performance rankings with an Elo score of 1470, a chess-style rating system that measures how often models beat each other in head-to-head comparisons based on user feedback.

3 weeks ago | drugdiscoverytrends.com | Brian Buntz

An AI-designed drug, rentosertib, from Insilico Medicine improved lung function by 98.4 mL in a 71-patient idiopathic pulmonary fibrosis study published June 3 in Nature Medicine, marking what may be the first peer-reviewed phase 2a result for a molecule generated, with its target discovered, entirely by generative AI.

3 weeks ago | rdworldonline.com | Brian Buntz

In many ways, the first half of 2025 hasn’t been kind to the biotech sector’s growth trajectory. Headwinds from constrained research funding and shifting market dynamics have led to strategic recalibrations for many, including instrument makers like 10x Genomics. But the company’s Chief Technology Officer Michael Schnall-Levin is optimistic about the bigger picture. “I think on the fundamentals, it’s actually a pretty exciting time,” Schnall-Levin said.